Firm behind Singapore's potential vaccine to test freeze-dried version

Arcturus Therapeutics is looking at a freeze-dried version of its mRNA vaccine that could work well at room temperature. PHOTO: REUTERS
New: Gift this subscriber-only story to your friends and family

Singapore's potential Covid-19 vaccine could well be one which can be manufactured, shipped and stored with ease, as the company behind it is working on a version which does not need ultra-cold conditions for it to survive.

Arcturus Therapeutics, a US-based biotechnology company developing a Covid-19 vaccine with the Duke-NUS Medical School here, is looking at a lyophilised or freeze-dried version of its mRNA vaccine that could work well at room temperature, unlike other similar vaccines.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and straitstimes.com

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.

A version of this article appeared in the print edition of The Straits Times on October 08, 2020, with the headline Firm behind Singapore's potential vaccine to test freeze-dried version. Subscribe